Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2006 4
2007 8
2008 5
2009 6
2010 3
2011 7
2012 4
2013 3
2014 9
2015 6
2016 5
2017 4
2018 2
2019 3
2020 4
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
COVID-19 crisis and cancer.
Bartsch R, Hilbe W. Bartsch R, et al. Among authors: hilbe w. Memo. 2022;15(2):98-99. doi: 10.1007/s12254-022-00812-x. Epub 2022 Jun 7. Memo. 2022. PMID: 35693202 Free PMC article. No abstract available.
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.
Wörmann B, Bokemeyer C, Burmeister T, Köhne CH, Schwab M, Arnold D, Blohmer JU, Borner M, Brucker S, Cascorbi I, Decker T, de Wit M, Dietz A, Einsele H, Eisterer W, Folprecht G, Hilbe W, Hoffmann J, Knauf W, Kunzmann V, Largiadèr CR, Lorenzen S, Lüftner D, Moehler M, Nöthen MM, Pox C, Reinacher-Schick A, Scharl A, Schlegelberger B, Seufferlein T, Sinn M, Stroth M, Tamm I, Trümper L, Wilhelm M, Wöll E, Hofheinz RD. Wörmann B, et al. Among authors: hilbe w. Oncol Res Treat. 2020;43(11):628-636. doi: 10.1159/000510258. Epub 2020 Oct 23. Oncol Res Treat. 2020. PMID: 33099551 Free article. Review.
Circumnavigating the challenges of COVID-19 in oncology.
Fuereder T, Gunsilius E, Bartsch R, Hilbe W; editors of memo. Fuereder T, et al. Among authors: hilbe w. Memo. 2020;13(2):135-138. doi: 10.1007/s12254-020-00611-2. Epub 2020 May 7. Memo. 2020. PMID: 32382356 Free PMC article. No abstract available.
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A. Papachristofilou A, et al. Among authors: hilbe w. J Immunother Cancer. 2019 Feb 8;7(1):38. doi: 10.1186/s40425-019-0520-5. J Immunother Cancer. 2019. PMID: 30736848 Free PMC article. Clinical Trial.
Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.
Schwarz M, Kocher F, Niedersuess-Beke D, Rudzki J, Hochmair M, Widmann G, Hilbe W, Pircher A. Schwarz M, et al. Among authors: hilbe w. Clin Lung Cancer. 2019 May;20(3):e247-e250. doi: 10.1016/j.cllc.2018.12.006. Epub 2018 Dec 19. Clin Lung Cancer. 2019. PMID: 30635258 No abstract available.
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, Cseh A, Fritz R, Filipits M. Hochmair MJ, et al. Among authors: hilbe w. Target Oncol. 2019 Feb;14(1):75-83. doi: 10.1007/s11523-018-0612-z. Target Oncol. 2019. PMID: 30539501 Free PMC article. Clinical Trial.
70 results